Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Even if the commissioner determines the grounds for withdrawing Avastin's accelerated approval in breast cancer have been met, she could decide to retain the claim while Genentech conducts additional confirmatory trials, the hearing notice explains.

You may also be interested in...



Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP

Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.

Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP

Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.

Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP

Agency reorganizes cancer drug reviews by disease type, while keeping leadership, as expected. After scheduled actions, applications will be migrating to their designated areas within the renamed Office of Hematology and Oncology Products.

Related Content

Topics

UsernamePublicRestriction

Register

PS072337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel